Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

A number of other research analysts have also recently issued reports on the stock. StockNews.com initiated coverage on shares of Moleculin Biotech in a report on Thursday, March 13th. They issued a “sell” rating for the company. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.

Moleculin Biotech Stock Performance

MBRX opened at $1.06 on Monday. The firm’s 50-day moving average price is $1.34 and its 200-day moving average price is $2.01. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $6.23.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.